BioNTech

BioNTech’s Melbourne mRNA Plant and Its Cancer Readouts Share One Test: Does Capacity Become Patient Benefit?

angelina -

BioNTech’s Two Cancer Readouts Point in Opposite Directions — and Neither Settles the Case

Brett Shapiro -

BioNTech Hands Gilead the Chemo Slot in ROSETTA Breast-01 — A Trial Design, Not a Verdict

angelina -

BioNTech’s BNT113 Misses Progression-Free Survival Goal, but AHEAD-MERIT Trial Soldiers On

kashif hafeez -

BioNTech’s AHEAD-MERIT Setback and Insider Sales Test Investor Patience

kashif hafeez -

BioNTech’s BNT113 Setback: Wall Street Keeps the Faith as Mainz Plays the Long Game

BioNTech’s Friday Rally Wasn’t About BioNTech — and That’s the Whole Story

kashif hafeez -

BioNTech Slides as Biotech Retreat Overshadows Insider Sale and Plant Closures

Brett Shapiro -

BioNTech Trims Its Industrial Past to Fund a Cancer Future

kashif hafeez -

BioNTech Exits Vaccine Manufacturing With 1,860 Job Cuts, Turns Full Attention to Cancer

BioNTech’s Institutional Handover Meets a Fresh Regulatory Win

angelina -

BioNTech’s Slide Has Little to Do With BioNTech

kashif hafeez -

BioNTech’s Shrinking Footprint: What the Factory Sale Talks and Sahin’s September Trades Say About the Pipeline Bet

Brett Shapiro -

BioNTech’s September Crossroads: A Pipeline Setback, a Factory Fire Sale, and a CEO Who Hasn’t Started Yet

Brett Shapiro -

BioNTech’s September Pivot: Seoul Data and Factory Calls Will Test Whether One Trial Halt Defines the Story

kashif hafeez -
123...16Page 1 of 16